

**Technology Advisory Committee C Interests Register**  
**Brolucizumab for treating diabetic macular oedema [ID3902]**  
**Publication Date: 31/08/2022**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	In 2020 Mr Chambers helped co-ordinate a training programme run by the University of Utrecht in Real World Evidence for Roche, manufacturer of a possible comparator therapy, but this did not involve any specific consideration of Roche products.  In 2021-22, Mr Chambers participated in an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer).	N/A	13.06.2022	N/A	It was agreed his declarations would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas has attended paid advisory boards with Novartis, and with Roche, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis).	N/A	21.06.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.

Mr Winfried Amoaku	Clinical expert	Direct – financial	<p>Mr Amoaku has participated in ad hoc advisory boards for AbbVie, Alcon, Alimera, Allergan, Bayer, Novartis, Pfizer and Roche for which he has received honoraria (2006-2021).</p> <p>Mr Amoaku has advised Roche on current and potential future treatment pathways for Geographic Atrophy (2018-2021).</p> <p>Mr Amoaku has received educational travel grants from Alimera, Allergan, Bayer, Novartis and Pfizer (2007-2021).</p> <p>Mr Amoaku is a member of</p> <ul style="list-style-type: none"> <li>the Data &amp; Safety Monitoring Board for Bioeq FYB203-03-01 MAGELLAN-AMD: 2020-23.</li> <li>the Steering Committee for Apellis (2021-23).</li> <li>The UK FRB! Steering Committee (2020 to date).</li> </ul> <p>Mr Amoaku's institution, the University of Nottingham, has received funding for research sponsored by Allergan,</p>	N/A	28.02.2022	N/A	It was agreed that his declarations would not prevent Mr Amoaku from providing expert advice to the committee.
--------------------	-----------------	--------------------	---	-----	------------	-----	--

		Indirect – financial	<p>Bausch and Lomb, Gyroscope, Novartis (including the KESTRAL study), Pfizer and Roche (2004-2021) which he has participated in. The institution has also received unconditional research grants from Allergan, Bayer and Novartis.</p> <p>Mr Amoaku is the Chair of the UK Diabetic Retinopathy Consensus (Guidelines) Group which developed Guidelines with publication costs covered by an educational grant from Allergan.</p> <p>Mr Amoaku has received medical writing assistance provided by Prescript Communications (UK) which was partly supported by Alimera Sciences through an unrestricted grant.</p>				
Mr Luke Nicholson	Clinical expert	Direct – financial	<p>Mr Nicholson has received speaker fees from Bayer, Allergan and Heidelberg and research funding from Optos.</p> <p>He has attended an advisory board for Allergan.</p>	N/A	19.03.2022	N/A	It was agreed that his declarations would not prevent Mr Nicholson from providing expert advice to the committee.

Stephen Scowcroft	Patient expert	Direct – financial	Mr Scowcroft's employer, the Macular Society, receives financial support from a number of pharma companies. None of the companies have direct editorial input into Macular Society information or activities.	N/A	23.03.2022	N/A	It was agreed that his declaration would not prevent Mr Scowcroft from providing expert advice to the committee.
-------------------	----------------	--------------------	---	-----	------------	-----	--